Latest Health News
Igyxos Biotherapeutics Announces Positive Results from Phase 1 Trial of IGX12, its First-in-Class Monoclonal Antibody for the Treatment of Male and Female Infertility
December 10, 2025 04:00 ET | Source: Igyxos TOURS, France, Dec. 10,…
Teleflex Announces Sale of Acute Care, Interventional Urology, and OEM Businesses for $2.03 Billion
WAYNE, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a…
Xcell Biosciences and Culture Biosciences Partner to Advance Cell Therapy Quality Through AI and Machine Learning
SAN FRANCISCO, CALIFORNIA, UNITED STATES, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Xcell…
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
- First patient in the world treated with Alpha DaRT® in the…
Zelluna ASA – Mandatory notification of trade
Reference is made to the private placement (the "Private Placement") and the retail…
Ipsen – November 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares composing…
Nelipak Acquires Merrills Packaging
CRANSTON, R.I., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Nelipak® Corporation (“Nelipak”), a…
Lynozyfic (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
All three dose groups (50 mg, 100 mg and 200 mg) showed…
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
93% overall response and 76% complete response rates with median progression-free survival…
